# US 2023/0056900 A1 · Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056900 A1
- Document ID: US20230056900A1
- Status: Published application
- Kind: A1
- Application number: 17/750,851
- Filed: 2022-05-23
- Published: 2023-02-23
- Earliest claimed: 2013-03-15
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Gregory Alan Lazar
- Web page: https://patentgrep.com/patent/US20230056900A1

## CPC

- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2893: {against CD52}
- C07K 16/32: against translation products of oncogenes
- C07K 16/4291: {against IgE}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.

## Claims

### Claim at position 1

-6. (canceled)

### Claim 7

An antibody comprising:
a) a light chain at least about 95% identical to SEQ ID NO:77; and
b) a heavy chain at least about 95% identical to SEQ ID NO:76,
wherein said antibody binds to human CD20, and wherein said heavy chain comprises S239D and I332E amino acid substitutions according to EU numbering.

### Claim 8 (depends on 7)

A nucleic acid composition comprising:
a) a first nucleic acid encoding the light chain of claim 7; and
b) a second nucleic acid encoding the heavy chain of claim 7.

### Claim 9 (depends on 8)

An expression vector composition comprising:
a) a first expression vector comprising the first nucleic acid of claim 8; and
b) a second expression vector comprising the second nucleic acid of claim 8.

### Claim 10 (depends on 9)

A host cell comprising the expression vector composition of claim 9.

### Claim 11 (depends on 1, 10)

A method of producing the antibody of claim 1 comprising culturing the host cell of claim 10 under suitable conditions wherein said antibody is expressed, and recovering said antibody.
